OPKO Health and Entera Bio expand partnership for oral PTH tablet Feb 4, 2026 08:02AM
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism Feb 4, 2026 08:00AM
OPKO Health and Entera Bio abstract selected for ESPEN Congress Jul 8, 2025 08:03AM
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress Jul 8, 2025 08:00AM
OPKO Health (OPK) and Entera Bio (ENTX) Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation Jun 25, 2025 08:05AM
View Older Stories

Jun 25, 2025 08:00AM OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
Mar 17, 2025 08:01AM OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement
Mar 17, 2025 08:00AM OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Jan 27, 2025 08:00AM Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Nov 8, 2024 04:05PM Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Nov 7, 2024 08:00AM Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®
Sep 25, 2024 08:31AM Entera Bio Ltd. (ENTX) and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin Peptide Tablet Candidate
Sep 25, 2024 08:30AM Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Aug 9, 2024 04:05PM Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Mar 20, 2024 08:00AM Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Feb 28, 2024 09:31AM NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st
Feb 5, 2024 08:09AM NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China
Jun 28, 2023 06:45AM Pfizer (PFE) and OPKO (OPK) Announce FDA Approval of NGENLA
Jun 28, 2023 06:45AM FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Feb 9, 2023 07:05AM BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings
May 2, 2022 07:45AM Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
Feb 15, 2022 11:09AM Pfizer (PFE), OPKO’s (OPK) Once-Weekly NGENLA Injection Receives Marketing Authorization in European Union for Treatment of Pediatric GHD
Feb 15, 2022 11:08AM Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Jan 24, 2022 09:25AM Pre-Open Stock Movers 01/24: (EXTN) (KSS) (UL) Higher; (OPK) (MSTR) (MARA) Lower (more...)
Jan 21, 2022 04:30PM Pfizer (PFE) and OPKO (OPK) Receive CRL for BLA for Somatrogon for Pediatric Growth Hormone Deficiency
Jan 21, 2022 04:30PM Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Jan 20, 2022 08:03AM OPKO Health (OPK) and Pfizer (PFE) Announce Approval of NGENLA in Japan
Jan 20, 2022 08:00AM Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency
Jan 18, 2022 07:00AM Sema4 (SMFR) Acquires GeneDx from OPKO (OPK)
Jan 18, 2022 07:00AM Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Jan 18, 2022 07:00AM Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Sep 24, 2021 04:26PM OPKO Health (OPK) and Pfizer (PFE) Extend U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Sep 24, 2021 04:24PM Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Jun 17, 2021 07:06AM Horizon Therapeutics (HZNP) Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 17, 2021 07:00AM Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Feb 26, 2021 06:39AM Pfizer (PFE) and OPKO (OPK) Announce EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Feb 26, 2021 06:30AM EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Jan 4, 2021 06:46AM Pfizer (PFE), OPKO Health (OPK) Announce FDA Accepts Regulatory Submission for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Jan 4, 2021 06:45AM US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Oct 8, 2020 06:49AM Pfizer (PFE) Phase 3 Once-Weekly Investigational Study of Somatrogon to Treat Children with GHD Met its Primary Endpoint
Oct 8, 2020 06:45AM Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
Oct 21, 2019 08:06AM OPKO Health (OPK), Pfizer (PFE) announced Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with GHD met its primary endpoint
Oct 21, 2019 08:00AM OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
Sep 5, 2019 07:03AM OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement
Sep 4, 2019 07:03AM OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement
Nov 15, 2017 07:05AM Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update
Nov 2, 2017 08:05AM Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
Oct 31, 2017 09:06AM Xenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEO
Oct 31, 2017 09:05AM Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
Oct 2, 2017 10:45AM Xenetic Biosciences Provides Update on Annual Meeting of Stockholders
Sep 12, 2017 08:30AM OPKO’s GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings
Aug 23, 2017 08:05AM Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders
Aug 15, 2017 08:05AM Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update
Aug 14, 2017 05:00PM Xenetic Biosciences (XBIO) Announces Appointment of Three Directors to the Board
Aug 14, 2017 05:00PM Xenetic Biosciences Announces Appointment of Three Directors to the Board
View Older Stories